Original Article

Risk, Outcomes, and Predictors of Clostridium difficile Infection in Lymphoma: A Nationwide Study

Authors: Sanjay Bhandari MD, Ramesh Kumar Pandey MD, Sumit Dahal MD, Muhammad Shahreyar MD, Binod Dhakal MD, Pinky Jha MD, Thangam Venkatesan MD, Kia Saeian MD, MS

Abstract

Objective: The risk of Clostridium difficile infection (CDI) has not been well studied in patients with lymphoma. We thus sought to determine the risk of CDI in hospitalizations with lymphoma along with its trend, outcomes, and predictors using a large database.

Methods: Hospital discharge data from the Nationwide Inpatient Sample (NIS) from 2007 to 2011 were used for the study. Using the International Classification of Diseases, Ninth Revision, Clinical Modification codes, all adult patients aged 18 years or older having a primary diagnosis of lymphoma were queried for the presence of CDI as any of the secondary diagnoses. The risk of CDI in lymphoma and its yearly trend were assessed. We performed multivariate logistic regression to determine the independent risk factors of CDI in lymphoma. Furthermore, we studied mortality and other adverse outcomes of CDI in patients with lymphoma.

Results: There were 236,312 discharges (weighted) with the primary diagnosis of lymphoma. CDI was present in 2.13% of patients with lymphoma versus 0.8% in the nonlymphoma group (P < 0.001). On multivariate analysis, the significant predictors of CDI in lymphoma were presence of infection (odds ratio [OR] 3.1, 95% confidence interval [CI] 2.7–3.6), stem cell transplant (OR 2.7, 95% CI 2.3–3.4), graft-versus-host disease (OR 1.9, 95% CI 1.4–2.8), race (Asian vs white, OR 1.6, 95% CI 1.1–2.4), chemotherapy (OR 1.6, 95% CI 1.4–1.8), gastrointestinal surgery (OR 1.4, 95% CI 1.2–1.7), and Charlson Comorbidity Index (CCI) (CCI of 2 vs 0–1: OR 1.2, 95% CI 1.1–1.4; CCI of 3 vs 0–1: OR 1.3, 95% CI 1.03–1.6). CDI in lymphoma was associated with worse hospital outcomes such as increased mortality (17% vs 8%), increased length of stay (23.6 vs 9.9 days), mean total hospital charges ($197,015 vs $79,392), rate of intubation (13% vs 4% vs 13%), and rate of total parenteral nutrition (11% vs 3%).

Conclusions: Hospitalization with lymphoma was associated with an increased risk of CDI. The significant predictors for CDI in lymphoma were infection, stem cell transplant, graft-versus-host disease, race, chemotherapy, gastrointestinal surgery, and Charlson Comorbidity Index. CDI in lymphoma was associated with increased mortality and other adverse outcomes warranting a need of more vigilance for CDI in patients with lymphoma.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:825-834.
 
2. Freeman J, Bauer MP, Baines SD, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010;23:529-549.
 
3. George RH, Symonds JM, Dimock F, et al. Identification of Clostridium difficile as a cause of pseudomembranous colitis. Br Med J 1978;1:695.
 
4. Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014;69:881-891.
 
5. Smits WK, Lyras D, Lacy DB, et al. Clostridium difficile infection. Nat Rev Dis Primers 2016;2:16020.
 
6. Brown E, Talbot GH, Axelrod P, et al. Risk factors for Clostridium difficile toxin-associated diarrhea. Infect Control Hosp Epidemiol 1990;11:283-290.
 
7. McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 1990;162:678-684.
 
8. Neemann K, Freifeld A. Clostridium difficile-associated diarrhea in the oncology patient. J Oncol Pract 2017;13:25-30.
 
9. Chopra T, Chandrasekar P, Salimnia H, et al. Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clin Transplant 2011;25:E82-87.
 
10. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011;365:1693-1703.
 
11. Heard SR, Wren B, Barnett MJ, et al. Clostridium difficile infection in patients with haematological malignant disease. Risk factors, faecal toxins and pathogenic strains. Epidemiol Infect 1988;100:63-72.
 
12. Talon D, Bailly P, Delmee M, et al. Use of pulsed-field gel electrophoresis for investigation of an outbreak of Clostridium difficile infection among geriatric patients. Eur J Clin Microbiol Infect Dis 1995;14:987-993.
 
13. Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993;17:109-113.
 
14. Fainstein V, Bodey GP, Fekety R. Relapsing pseudomembranous colitis associated with cancer chemotherapy. J Infect Dis 1981;143:865.
 
15. Dubberke ER, Butler AM, Reske KA, et al. Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients. Emerg Infect Dis 2008;14:1031-1038.
 
16. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012;55(suppl 2):S88-S92.
 
17. Sammons JS, Localio R, Xiao R, et al. Clostridium difficile infection is associated with increased risk of death and prolonged hospitalization in children. Clin Infect Dis 2013;57:1-8.
 
18. Zhang S, Palazuelos-Munoz S, Balsells EM, et al. Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study. BMC Infect Dis 2016;16:447.
 
19. Luo R, Greenberg A, Stone CD. Outcomes of Clostridium difficile infection in hospitalized leukemia patients: a nationwide analysis. Infect Control Hosp Epidemiol 2015;36:794-801.
 
20. Pant C, Anderson MP, O'Connor JA, et al. Association of Clostridium difficile infection with outcomes of hospitalized solid organ transplant recipients: results from the 2009 Nationwide Inpatient Sample database. Transpl Infect Dis 2012;14:540-547.
 
21. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7-30.
 
22. Apostolopoulou E, Raftopoulos V, Terzis K, et al. Infection Probability Score: a predictor of Clostridium difficile-associated disease onset in patients with haematological malignancy. Eur J Oncol Nurs 2011;15:404-409.
 
23. Healthcare Cost and Utilization Project. NIS database documentation. www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp. Published March 2017. Accessed August 30, 2017.
 
24. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
 
25. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-1139.
 
26. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med 2008;359:1932-1940.
 
27. Spadão F, Gerhardt J, Guimaraes T, et al. Incidence of diarrhea by Clostridium difficile in hematologic patients and hematopoietic stem cell transplantation patients: risk factors for severe forms and death. Rev Inst Med Trop Sao Paulo 2014;56:325-331.
 
28. Bishop KD, Castillo JJ. Risk factors associated with Clostridium difficile infection in adult oncology patients with a history of recent hospitalization for febrile neutropenia. Leuk Lymphoma 2012;53:1617-1619.
 
29. Rodriguez Garzotto A, Mérida Garcia A, Muñoz Unceta N, et al. Risk factors associated with Clostridium difficile infection in adult oncology patients. Support Care Cancer 2015;23:1569-1577.
 
30. McCaleb RV, Gandhi AS, Clark SM, et al. Clinical outcomes of acid suppressive therapy in hematology/oncology patients at an academic medical center. Ann Pharmacother 2016;50:541-547.
 
31. Gifford AH, Kirkland KB. Risk factors for Clostridium difficile-associated diarrhea on an adult hematology-oncology ward. Eur J Clin Microbiol Infect Dis 2006;25:751-755.
 
32. Gorschlüter M, Glasmacher A, Hahn C, et al. Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 2001;33:786-791.
 
33. Chakrabarti S, Lees A, Jones SG, et al. Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse mortality. Bone Marrow Transplant 2000;26:871-876.
 
34. Khanafer N, Neuraz A, Bénet T, et al. Acute graft-versus-host disease, invasive aspergillosis and Clostridium difficile colitis after peripheral blood stem cell transplantation: a complex network of causalities and a challenge for prevention. Anaerobe 2015;33:98-100.
 
35. Callejas-Diaz A, Gea-Banacloche JC. Clostridium difficile: deleterious impact on hematopoietic stem cell transplantation. Curr Hematol Malig Rep 2014;9:85-90.
 
36. Stringer AM. Interaction between host cells and microbes in chemotherapy-induced mucositis. Nutrients 2013;5:1488-1499.
 
37. Leslie JL, Huang S, Opp JS, et al. Persistence and toxin production by Clostridium difficile within human intestinal organoids result in disruption of epithelial paracellular barrier function. Infect Immun 2015;83:138-145.
 
38. Dubberke ER, Reske KA, Srivastava A, et al. Clostridium difficile-associated disease in allogeneic hematopoietic stem-cell transplant recipients: risk associations, protective associations, and outcomes. Clin Transplant 2010;24:192-198.
 
39. Arango JI, Restrepo A, Schneider DL, et al. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant 2006;37:517-521.
 
40. Willems L, Porcher R, Lafaurie M, et al. Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 2012;18:1295-1301.
 
41. Trifilio SM, Pi J, Mehta J. Changing epidemiology of Clostridium difficile-associated disease during stem cell transplantation. Biol Blood Marrow Transplant 2013;19:405-409.
 
42. Neemann K, Minhas V, Loberiza FR, et al. Transplant related outcomes in patients with hematopoietic stem cell transplant with Clostridium difficile associated diarrhea. Leuk Lymphoma 2015;56:260-262.
 
43. Guddati AK, Kumar G, Ahmed S, et al. Incidence and outcomes of Clostridium difficile-associated disease in hematopoietic cell transplant recipients. Int J Hematol 2014;99:758-765.
 
44. Schalk E, Bohr UR, Konig B, et al. Clostridium difficile-associated diarrhoea, a frequent complication in patients with acute myeloid leukaemia. Ann Hematol 2010;89:9-14.
 
45. Ali M, Ananthakrishnan AN, Ahmad S, et al. Clostridium difficile infection in hospitalized liver transplant patients: a nationwide analysis. Liver Transpl 2012;18:972-978.
 
46. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998;40:1-15.
 
47. Lofgren ET, Cole SR, Weber DJ, et al. Hospital-acquired Clostridium difficile infections: estimating all-cause mortality and length of stay. Epidemiology 2014;25:570-575.
 
48. Zimlichman E, Henderson D, Tamir O, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med 2013;173:2039-2046.